Salud financiera de hoja de balance de Tharimmune

Salud financiera controles de criterios 6/6

Tharimmune tiene un patrimonio de los accionistas total de $7.0M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $8.9M y $1.8M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$8.43m
Patrimonio	US$7.05m
Total pasivo	US$1.84m
Activos totales	US$8.89m

Actualizaciones recientes sobre salud financiera

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Feb 14

Recent updates

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Feb 14

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($8.9M) de THAR superan a sus pasivos a corto plazo ($1.8M).

Pasivo a largo plazo: THAR no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: THAR está libre de deudas.

Reducción de la deuda: THAR no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: THAR tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: THAR dispone de suficiente cash runway para 1.4 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 55.2% cada año.

Salud financiera de hoja de balance de Tharimmune

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Tharimmune Announces 1-for-15 Reverse Stock Split, Intends to Bring it into Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Tharimmune Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Hillstream Biopharma Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Hillstream BioPharma, Inc. announced delayed 10-Q filing

Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Recent updates

Tharimmune, Inc. Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, Its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune, Inc. Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune Announces 1-for-15 Reverse Stock Split, Intends to Bring it into Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Tharimmune, Inc., Annual General Meeting, May 14, 2024

Tharimmune, Inc. Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Tharimmune, Inc. Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Tharimmune, Inc. Announces Initiation of Phase 1 Clinical Trial of TH104

Tharimmune, Inc. Announces Positive Topline Data with Th104, Its Lead Candidate for Moderate-To-Severe Pruritus in Chronic Liver Disease Patients

Tharimmune Reports Positive Phase 1 Data on Th104, Its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (Pbc)

Tharimmune, Inc. has completed a Follow-on Equity Offering.

Tharimmune Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Tharimmune, Inc. has filed a Follow-on Equity Offering.

Hillstream Biopharma Progressing Towards Acquiring Clinical Stage Asset

New major risk - Shareholder dilution

Less than half of directors are independent

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2 HER3 Solid Tumors Via Bispecific and ADC Antibodies and Biologics

Hillstream Biopharma Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Hillstream BioPharma, Inc. announced delayed 10-Q filing

Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Hillstream BioPharma, Inc. Announces Initial Results Evaluating the Synergy

Hillstream BioPharma, Inc. Announces Acceptance of Abstract At AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-Functional Inhibitor for Solid Tumors & Leukemias

Hillstream BioPharma, Inc. to Host Virtual R&D Day to Showcase Its Emerging Immuno-Oncology Pipeline Targeting Drug-Resistant Cancers

Hillstream BioPharma Receives Non-Compliance Written Notice from the Nasdaq

Hillstream BioPharma, Inc., Annual General Meeting, Aug 08, 2022

Hillstream BioPharma, Inc. (NasdaqCM:HILS) announces an Equity Buyback for $1 million worth of its shares.

Hillstream BioPharma, Inc. announced delayed annual 10-K filing

Hillstream BioPharma, Inc. has completed an IPO in the amount of $15 million.

No independent directors

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera